

# Dynamic change of transcription pausing through modulating NELF protein stability regulates granulocytic differentiation

Xiuli Liu,<sup>1-3</sup> Aishwarya A. Gogate,<sup>2,3</sup> Melodi Tastemel,<sup>1-4</sup> Venkat S. Malladi,<sup>2,3</sup> Huiyu Yao,<sup>5</sup> Kim Nguyen,<sup>1-3</sup> Lily Jun-Shen Huang,<sup>5</sup> and Xiaoying Bai<sup>1-4</sup>

<sup>1</sup>Laboratory of Molecular Genetics of Blood Development, <sup>2</sup>Cecil H. and Ida Green Center for Reproductive Biology Sciences, <sup>3</sup>Division of Basic Reproductive Biology Research, Department of Obstetrics and Gynecology, <sup>4</sup>Genetics, Development and Disease Graduate Program, and <sup>5</sup>Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX

## Key Points

- Granulocytic differentiation triggers a decrease of NELF protein abundance.
- Downregulation of NELF-mediated transcription pausing is necessary and sufficient for granulocytic differentiation.

The negative elongation factor (NELF) complex is a metazoan-specific factor essential for establishing transcription pausing. Although NELF has been implicated in cell-fate regulation, the cellular regulation of NELF and its intrinsic role in specific lineage differentiation remains largely unknown. Using mammalian hematopoietic differentiation as a model system, here we identified a dynamic change of NELF-mediated transcription pausing as a novel mechanism regulating hematopoietic differentiation. We found a sharp decrease of NELF protein abundance upon granulocytic differentiation and a subsequent genome-wide reduction of transcription pausing. This loss of pausing coincides with activation of granulocyte-affiliated genes and diminished expression of progenitor markers. Functional studies revealed that sustained expression of NELF inhibits granulocytic differentiation, whereas NELF depletion in progenitor cells leads to premature differentiation toward the granulocytic lineage. Our results thus uncover a previously unrecognized regulation of transcription pausing by modulating NELF protein abundance to control cellular differentiation.

## Introduction

Hematopoietic cell differentiation is initiated by hematopoietic stem cells, a rare cell population with the capacity to self-renew and differentiate through hierarchically organized progenitor stages to generate all mature blood lineages including erythrocytes, platelets, granulocytes, monocytes, and lymphocytes. This well-characterized differentiation process has provided a powerful model to study transcriptional mechanisms in cellular differentiation and lineage-fate selection.

Transcription mechanisms controlling hematopoietic differentiation can regulate different steps of transcription, including the pausing of RNA polymerase II (Pol II) during early transcription elongation. Unveiled by biochemical and genomic studies, transcriptionally engaged Pol II frequently pauses after initiation and accumulates at 20 to 60 nucleotides downstream of the promoter region, stabilized by pausing factors.<sup>1,2</sup> The most extensively studied pausing factors are the DRB sensitivity-inducing factor (DSIF) and the negative elongation factor (NELF) complex.<sup>3-5</sup> Release of paused Pol II into productive elongation is triggered by the recruitment of the positive transcription elongation factor b (P-TEFb), which phosphorylates NELF, DSIF, and the Pol II C-terminal domain, leading to the conversion of DSIF into an elongation-stimulating factor and the dissociation of NELF.<sup>6-8</sup> Unlike DSIF that has function in both pausing and elongation,<sup>9</sup> NELF is proposed mainly as a pausing factor to hold engaged Pol II within the promoter-proximal region.<sup>10</sup> Composed of 4 subunits (A, B, C/D, and E), NELF executes its role in

Submitted 11 May 2017; accepted 30 June 2017. DOI 10.1182/bloodadvances.2017008383.

The full-text version of this article contains a data supplement.

The GRO-seq data reported in this article have been deposited in the Gene Expression Omnibus database (accession number GSE98555).

© 2017 by The American Society of Hematology

Pol II pausing beyond simply inhibiting transcription. Studies of transcription profiles in NELF-depleted cells revealed more down-regulated genes than upregulated genes, suggesting a positive role of NELF in maintaining gene expression.<sup>11</sup> This was further supported by studies showing that NELF depletion causes either nucleosome reassembly on promoters or less recruitment of transcription initiation factors,<sup>11-14</sup> suggesting a role of paused Pol II in maintaining gene expression by facilitating initiation and generating a permissive chromatin state around the promoter region.

Despite the well-established role of NELF in regulating transcription pausing, the cellular regulation and function of NELF-mediated pausing in lineage differentiation remains to be explored. Using hematopoietic differentiation systems, here we identified a downregulation of NELF protein abundance upon induction of granulocytic differentiation from human and mouse hematopoietic progenitor cells. Genomic analyses further revealed a genome-wide change of transcription pausing correlated with NELF abundance. Manipulation of NELF expression demonstrated an inhibitory role of NELF-mediated Pol II pausing in granulocytic differentiation. Our studies unveil a novel regulation of NELF that is tightly linked to the biological function of pausing in cellular differentiation.

## Methods

### Cell culture, treatment, and transfection

Human hematopoietic CD34<sup>+</sup> progenitor cells isolated from peripheral blood of granulocyte colony-stimulating factor (G-CSF)-mobilized healthy volunteers were obtained from the Fred Hutchinson Cancer Research Center. Before differentiation, cells were expanded in StemSpan SFEM II medium (StemCell Technologies Inc) with 1× CC100 cytokine mix (StemCell Technologies Inc) and 2% penicillin-streptomycin (P/S) for 5 to 6 days. At the end of the expansion period, cells were reseeded in differentiation medium for up to 14 days with media change every other day. Erythroid differentiation medium contains SFEM II plus 2% P/S, 20 ng/mL stem cell factor, 1 U/mL erythropoietin (Epo), 5 ng/mL interleukin-3 (IL-3), 2 μM dexamethasone, and 1 μM β-estradiol. Myeloid differentiation was done by culturing CD34<sup>+</sup> cells in Iscove modified Dulbecco medium (IMDM) supplemented with 2% P/S, 10% fetal bovine serum (FBS), 100 ng/mL IL-3, and 100 ng/mL stem cell factor for 2 days, followed by addition of 10 ng/mL G-CSF on day 3. Flavopiridol (Sigma-Aldrich) treatment was done by adding 50 nM flavopiridol into differentiation medium.

Mouse 32Dcl3 cells were maintained in IMDM supplemented with 2% P/S, 10% FBS, and 5 ng/mL IL-3. Differentiation was induced by culturing cells in IMDM supplemented with 2% P/S, 15% FBS, and 100 ng/mL G-CSF.

Control and NELF short interfering RNAs (siRNAs) were purchased from Thermo Fisher. siRNAs were introduced into expanded CD34<sup>+</sup> cells by the Neon transfection system (Fisher) following the manufacturer's protocol.

The mouse *Nelf-E* complementary DNA (cDNA) was cloned in-frame into the pEF-Flag-Biotag vector<sup>15</sup> to generate an N-terminal Flag fusion molecule. 32D cells were transfected by the Neon transfection system with empty vector or pEF-Flag-NelfE and cultured in medium with 1 μg/mL puromycin to select stably transfected cells.

### Protein extraction and western blotting

Differentiating granulocytes were first incubated in 5.4 mM diisopropyl fluorophosphate for 15 minutes on ice to prevent

protein degradation caused by neutrophil-derived protease.<sup>16</sup> Washed cells were then lysed directly in 1× sodium dodecyl sulfate loading buffer followed by immediate boiling in the presence of 100 mM dithiothreitol for 10 minutes before loading on sodium dodecyl sulfate–polyacrylamide gel electrophoresis for western blotting. Antibodies used were: anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Bethyl), anti-NELFA (Bethyl), anti-NELFB (Bethyl), anti-NELFD (Santa Cruz Biotechnology), anti-NELFE (Santa Cruz Biotechnology), anti-Flag (Sigma-Aldrich).

### RNA extraction and quantitative reverse transcription PCR

RNA was isolated using the TRIzol reagent (Thermo Fisher), and subsequently treated with the DNA-free kit (Thermo Fisher). cDNA was synthesized with the SuperScript III kit (Thermo Fisher). Nascent RNA extraction was performed using the Click-iT Nascent RNA capture kit (Thermo Fisher) following the manufacturer's protocol. Quantitative polymerase chain reaction (qPCR) was performed on a Roche LightCycler 480 real-time PCR machine using the iQ SYBR Green Mastermix (Bio-Rad). Gene expression was analyzed relative to *β-actin* using the  $\Delta\Delta$  cycle threshold method. Primer sequences are available upon request.


### GRO-seq

Nuclei isolation, nuclear run-on, and library preparation were performed as previously described.<sup>17</sup> The global run-on sequencing (GRO-seq) data were analyzed using the groHMM software package described previously.<sup>18</sup> Further details about GRO-seq, including sample preparation and data analyses, can be found in the supplemental Methods.

## Results

### NELF protein levels are downregulated during granulocytic differentiation

To study the function of NELF in hematopoietic differentiation, we first examined NELF expression in hematopoietic progenitors and differentiated cells. Using human CD34<sup>+</sup> hematopoietic stem and progenitor cells (HSPCs) derived from mobilized adult peripheral blood, we followed published protocols<sup>19,20</sup> to differentiate HSPCs into either erythroid or granulocytic lineage induced by EPO or G-CSF, respectively. After confirming efficient differentiation of both lineages by May-Grünwald-Giemsa (MGG) staining (supplemental Figure 1A), cells at different stages of differentiation were examined for NELF protein by western blot analysis. Surprisingly, although NELF protein levels remained unchanged upon erythroid differentiation (supplemental Figure 1B), granulocytic differentiation induced an evident decrease of NELF protein starting from early stages of differentiation (Figure 1A). Consistent with previous studies that NELF subunits are interdependent for their protein stability,<sup>21</sup> all NELF subunits showed decreased protein levels with NELF-E protein showing the largest reduction (Figure 1A; supplemental Figure 1C). Quantitative reverse transcription PCR (qRT-PCR) analysis revealed no obvious change at the transcription level of NELF genes during early differentiation (Figure 1B), suggesting that NELF expression in differentiating granulocytes is regulated by a posttranscriptional mechanism. To test whether NELF is regulated




**Figure 1. Downregulation of NELF protein during granulocytic differentiation.** (A) Western blot of NELF subunits from different days during granulocytic differentiation of human CD34<sup>+</sup> HSPCs. GAPDH serves as a loading control. Quantification results are in supplemental Figure 1C. (B) qRT-PCR of messenger RNA (mRNA) levels of *NELF* genes during granulocytic differentiation of CD34<sup>+</sup> cells. Gene expression is normalized to  $\beta$ -actin and presented as fold change (FC) relative to day 0 ( $n = 3$ ; mean  $\pm$  standard error of the mean [SEM]). (C) Western blot of NELF subunits on differentiation day 3. MG132 treatment was done by adding 0.2  $\mu$ M MG132 overnight before harvesting cells for protein extraction. Quantification results are in supplemental Figure 1D. (D) Western blot of NELF subunits during neutrophil differentiation of mouse 32Dcl3 cell line. Quantification results are in supplemental Figure 1E. (E) qRT-PCR of mRNA levels of *Nelf* genes during neutrophil differentiation of mouse 32Dcl3 cells. Gene expression is normalized to  $\beta$ -actin and presented as fold change relative to day 0 ( $n = 3$ ; mean  $\pm$  SEM). (F) Western blot of NELF-A and -E subunits from cells isolated from mouse bone marrow (BM). NA, NELF-A; NB, NELF-B; NC/D, NELF-C/D; NE, NELF-E.

by proteasome-mediated protein degradation, differentiating granulocytes were treated with the 26S proteasome inhibitor MG132. This treatment markedly enhanced NELF protein levels, especially the level of NELF-E (Figure 1C; supplemental Figure 1D). Because NELF-E is reduced faster than other subunits (Figure 1A; supplemental Figure 1C), these results suggest that NELF-E might be the primary target for protein turnover triggered by granulocytic differentiation.

To test whether differentiation-induced change of NELF is specific to human cells, we examined NELF expression in a mouse myeloblastic cell line, 32Dcl3, which can be induced to neutrophils by G-CSF. Similar to human cells, differentiation induced a sharp decrease of NELF at the protein level but not the transcription level (Figure 1D-E). Again, NELF-E is the most downregulated subunit (supplemental Figure 1E). Finally, we tested whether NELF expression is differentially expressed *in vivo* during normal myeloid differentiation. Western blot analysis of cells isolated from mouse bone marrow revealed lower NELF protein levels in Gr-1<sup>+</sup> granulocytes compared with lineage-negative (Lin<sup>-</sup>) progenitor cells, whereas no such differences was detected in Ter119<sup>+</sup> erythroid cells (Figure 1F). Collectively, these results suggest an evolutionarily conserved regulation of NELF protein abundance during granulocytic differentiation that may play a physiological function in hematopoiesis *in vivo*.

## Genome-wide reduction of transcription pausing upon granulocytic differentiation

NELF is identified as a major transcription pausing factor. Downregulation of NELF upon granulocytic differentiation prompted us to ask whether there is a reduction of transcription pausing in differentiating granulocytes. To test this, we performed GRO-seq in CD34<sup>+</sup> HSPCs (day 0) and early differentiated (day 3) granulocytes. GRO-seq measures nascent RNA transcription from transcriptionally engaged RNA polymerase in isolated nuclei, thus reflecting a high-resolution distribution map of transcriptionally competent Pol II.<sup>22</sup> We conducted GRO-seq in 2 biological replicates and confirmed the reproducibility by correlation analysis (supplemental Figure 2A). Consistent with previous studies that Pol II pauses at the majority of metazoan genes,<sup>23-25</sup> metagene analysis of GRO-seq data from progenitor cells (day 0) revealed a typical genome-wide distribution pattern of transcriptionally engaged Pol II with high signals around the transcription start site (TSS) representing promoter-proximal-paused Pol II, and low signals along the gene body representing elongating Pol II (Figure 2A). In contrast, metagene analysis of early differentiated granulocytes (day 3) revealed a drastic reduction of Pol II occupancy around the TSS, suggesting a genome-wide reduction of Pol II pausing upon granulocytic differentiation (Figure 2A). To further verify metagene results, we calculated the pausing index (PI), a ratio of Pol II



**Figure 2. Genome-wide reduction of transcription pausing upon granulocytic differentiation.** (A) Metagenesis analysis showing transcriptionally engaged Pol II occupancy measured by GRO-seq on both sense and antisense strands in undifferentiated human CD34<sup>+</sup> HSPCs (day 0) and 3-day differentiated cells (day 3). (B) Left, An illustration for calculation of PI by the ratio of Pol II occupancy at promoter vs gene body. The promoter is defined from 300 bp upstream to the TSS. The gene body is defined from 300 bp downstream of the TSS until the end of the gene or up to 13 kb for genes longer than 13 kb. Right, Boxplot analysis to compare PI between HSPCs (day 0) and granulocytes (day 3). (C) Cumulative distribution function analysis to compare PI distribution in HSPCs (day 0) and granulocytes (day 3). (D) Genome browser captures of GRO-seq for granulocytic differentiation regulator genes (*PU.1* and *CSF3R*) and progenitor genes (*TAL1* and *GATA2*) in HSPCs (day 0) and granulocytes (day 3). Scale bar and gene diagram are depicted above the captures. Yellow shades highlight promoter peaks.

occupancy between the promoter (−300 bp ~ +300 bp centered at the TSS) and the gene body (+300 bp ~ up to 13 kb). Higher PI indicates stronger pausing. Consistent with the metagenesis analysis, PI is significantly decreased in granulocytes compared with progenitor cells (Figure 2B). Moreover, the cumulative distribution function analysis revealed that >85% of genes in granulocytes have decreased PI (Figure 2C). We concluded from these data that there is a genome-wide reduction of transcription pausing upon granulocytic differentiation, in line with the reduced abundance of NELF protein.


The elongating Pol II within gene bodies reflects the transcription strength of a gene. To identify genes that are differentially transcribed upon differentiation, we compared gene-body-associated Pol II (+300 bp ~ 13 kb) between progenitor cells and granulocytes. In total, 1779 genes were identified with at least a twofold change, including 471 upregulated (up) genes and 1308 downregulated (down) genes ( $P < .0001$ ). Gene-ontology (GO) analysis confirmed that upregulated genes contain several pathways involved in granulocyte function, such as cell migration, cell adhesion, proteolysis, and chemotaxis (supplemental Figure 2B). As expected, many genes involved in granulocytic differentiation, such as myeloid differentiation regulator genes *PU.1* and *CSF3R*, and granulocytic primary granule genes (*MPO*, *ELANE*, *AZU1*, and *PRTN3*) appear to be upregulated with increased gene-body-associated Pol II and a mild decrease of promoter-associated Pol II, suggesting enhanced Pol II release on these genes upon differentiation (Figure 2D; supplemental Figure 2C). In contrast, progenitor-related genes such as *GATA2* and *TAL1* have a dramatic reduction of Pol II occupancy

from both promoters and gene bodies (Figure 2D), consistent with the expected downregulation of progenitor genes during myeloid differentiation.

### Forced expression of NELF inhibits granulocytic differentiation

The downregulation of NELF protein in differentiating granulocytes suggests an inhibitory role of NELF in granulocytic differentiation. To test this, we ectopically expressed NELF-E, which is the most downregulated subunit upon granulocytic differentiation (Figure 1C; supplemental Figure 1D), in the murine 32Dcl3 myeloblastic cells. A Flag-tagged *Nelf-E* construct was stably transfected into cells and the expression of exogenous NELF-E was detected by anti-Flag antibody (Figure 3A). Transfected cells were induced to differentiation by adding G-CSF. Similar to the endogenous protein, differentiation caused a gradual reduction of the exogenous NELF-E (Figure 3B), further supporting rapid turnover of NELF-E protein triggered by differentiation. Notably, the level of endogenous NELF-A is mildly increased in cells overexpressing NELF-E (Figure 3B), supporting the view that NELF-E is the limiting subunit and increased NELF-E stabilizes other NELF components. Importantly, although the exogenous NELF-E level cannot be maintained at a high level due to rapid protein turnover, neutrophil differentiation was still severely blocked (Figure 3D), strongly suggesting that sustained NELF expression inhibits granulocytic differentiation.

To further distinguish whether the inhibitory role of NELF is through regulating transcription pausing and subsequent elongation, or reflects a pausing-independent function of NELF, we asked whether



**Figure 3. Forced expression of NELF-E inhibits granulocytic differentiation.** (A) Mouse 32Dcl3 cells were stably transfected with empty vector (ctrl) or Flag-tagged NELF-E (Flag-NE) and blotted with anti-Flag antibody. (B) Western blot of NELF-A and -E protein from 32D cells transfected with or without Flag-tagged NELF-E (Flag-NE). Protein extraction was done in undifferentiated cells (day 0) and cells differentiated for 1 day (d1) and 4 days (d4). Two independent Flag-NE transfected cell lines were shown. Red asterisk indicates Flag-NE that is slightly bigger than endogenous NELF-E. GAPDH is used as a loading control. (C) Representative images of MGG staining showing the morphology of human granulocytic differentiation from myeloblasts to mature segmented neutrophils. (D) MGG staining to compare the morphology of murine 32D cells expressing Flag-NE with control cells during neutrophil differentiation (original magnification  $\times 200$ ). (E) MGG staining to compare morphology of differentiating cells from human CD34<sup>+</sup> HSPCs treated with dimethyl sulfoxide (DMSO) vs flavopiridol (Flavo) (original magnification  $\times 200$ ). (D-E) The percentages of different cell types at various time points during differentiation are shown on the bar charts. Quantitative results represent average percentages by counting 100 cells per experiment from 3 independent experiments.

transcription elongation is required for granulocytic differentiation. Indeed, we found that treating differentiating granulocytes with flavopiridol, an inhibitor of the essential transcription elongation factor P-TEFb, severely blocked granulocytic differentiation of human HSPCs (Figure 3E). Together, these results suggest that granulocytic differentiation requires proper Pol II elongation, which could be promoted by reducing NELF-mediated pausing.


### NELF depletion leads to a genome-wide loss of transcription in progenitor cells

The results detailed in the previous sections suggest that downregulation of NELF-mediated pausing is necessary for proper granulocytic differentiation. We then asked how NELF depletion would affect progenitor cells. Using siRNAs targeting the NELF-B or -E subunit in human CD34<sup>+</sup> HSPCs, >80% knockdown efficiency was achieved at the protein level (Figure 4A-B). Moreover, knocking down NELF-B leads to a reduction of NELF-E, and vice versa (Figure 4A), consistent with the interdependency of NELF subunits. GRO-seq was conducted in cells transfected with a scramble siRNA or either of the NELF-siRNAs. High correlations between biologic replicates were observed (supplemental

Figure 3A). Metagene analysis of GRO-seq data revealed a near complete abolishment of Pol II pausing in progenitor cells depleted with either NELF-B or -E (Figure 4C; supplemental Figure 3B). PI calculation and cumulative distribution plot assays further confirmed the genome-wide loss of Pol II pausing in NELF-depleted cells (Figure 4D-E; supplemental Figure 3C), in line with a view that NELF is a major pausing factor in HSPCs.

We clustered differentially transcribed genes with more than a twofold change of gene-body-associated Pol II level in NELF-depleted cells into “up” and “down” groups. In NELF-E knockdown cells, 886 genes were identified as “up” genes and 3206 genes were identified as “down” genes ( $P < .0001$ ), respectively. A similar number of genes were also found in NELF-B knockdown cells (905 for “up” genes and 3242 for “down” genes). Importantly, there is a tremendous overlap (80% for “up” genes and 88% for “down” genes) of dysregulated genes between NELF-B and -E knockdown cells (Figure 4F), verifying the specificity of NELF knockdown.

Notably, metagene analysis revealed a relatively mild reduction of promoter-associated Pol II along with increased gene-body-associated Pol II on upregulated genes (supplemental Figure 3D),




**Figure 4. NELF depletion leads to a genome-wide loss of transcription in progenitor cells.** (A) Western blot of NELF-B and -E in human CD34<sup>+</sup> HSPCs transfected with a scramble siRNA (ctrl), or siRNA targeting NELF-B or -E. Protein extraction was done on day 3 posttransfection. GAPDH is used as a loading control. (B) Quantification of western blot in A by imageJ. Protein level is normalized to GAPDH and presented as fold change relative to control samples (n = 3; mean ± SEM; \*\*P < .01). (C) Metagene analysis showing Pol II occupancy measured by GRO-seq on both sense and antisense strands in human CD34<sup>+</sup> HSPCs transfected with control-siRNA (ctrl) or siRNA targeting NELF-E (NE-KD). Cells were collected on day 3 posttransfection. (D) Boxplot analysis to compare PI between cells transfected with a control-siRNA (ctrl), or siRNA targeting NELF-B (NB-KD) or -E (NE-KD). (E) Cumulative distribution function analysis to compare PI distribution in cells transfected with a control-siRNA (ctrl), or siRNA targeting NELF-E (NE-KD). (F) Venn diagram showing the overlap of upregulated (“up”) and downregulated genes (“down”) between NELF-B and NELF-E knockdown cells.

consistent with enhanced release of Pol II into elongation upon NELF knockdown. In contrast, the promoter-associated Pol II is almost completely abolished on downregulated genes along with reduced gene-body-associated Pol II (supplemental Figure 3D), indicating a complete loss of pausing on these genes upon NELF depletion. Moreover, “down” genes appear to be highly paused with significantly higher PI than “up” genes in control cells (supplemental Figure 3E). These results suggest that genes with high levels of pausing may require paused Pol II to maintain promoter accessibility for their transcription and therefore are prone to downregulation when pausing is lost. In contrast, genes with a relatively low level of pausing may not rely on paused Pol II to maintain an open promoter, and are more likely to be upregulated through enhanced elongation in the absence of pausing.

### NELF depletion in HSPCs promotes granulocytic differentiation

To test whether loss of pausing by NELF depletion is sufficient to activate granulocyte gene transcription in progenitor cells, we

examined Pol II levels on hematopoietic genes. We found that NELF depletion in HSPCs causes similar transcription changes as those in early differentiated granulocytes (Figure 2D), with an increase of gene-body-associated Pol II on granulocyte markers *PU.1*, *CSF3R*, *ELANE*, *AZU1*, and *PRTN3*, but an overall reduction of Pol II signal on progenitor genes (*GATA2* and *TAL1*) (Figure 5A; supplemental Figure 4A). In addition, consistent with the activation of JAK2/STAT3 and MEK/ERK pathways during myeloid differentiation, regulators of these pathways are also activated in both granulocytes and NELF-depleted HSPCs (Figure 5B; supplemental Figure 4B). The GRO-seq results were validated by qRT-PCR on nascent transcripts (supplemental Figure 4C). Moreover, comparison of differentially regulated gene lists revealed that many dysregulated genes are shared between early differentiated granulocytes and NELF-depleted HSPCs (supplemental Figure 4D). This is further supported by gene-set enrichment analysis, which revealed that “up” genes in NELF-depleted cells are markedly enriched for genes induced by granulocytic differentiation, whereas “down” genes in



**Figure 5. NELF depletion in HSPCs promotes granulocytic differentiation.** (A) Genome browser captures of GRO-seq for granulocytic differentiation regulator genes (*PU.1* and *CSF3R*) and progenitor genes (*TAL1* and *GATA2*) in NELF-depleted HSPCs. Scale bar and gene diagram are depicted above the captures. Yellow shades highlight promoter peaks. (B) Genome browser captures of GRO-seq for *STAT3* and *MAPK1* to compare transcription activity among HSPCs (day 0), 3-day differentiated granulocytes (*Gra\_d3*) and NELF-depleted HSPCs (*NB-KD\_d0* and *NE-KD\_d0*). (C) Gene-set enrichment analysis plots to compare differentially regulated genes between NELF-depleted HSPCs and 3-day differentiated granulocytes. Genes upregulated (left) or downregulated (right) in NELF-depleted HSPCs are indicated as black bars in the middle. A strong bias for these genes to also be upregulated (left) or downregulated (right) upon granulocytic differentiation is reflected in the top plots. (D) MGG staining to compare cell morphology between control cells (ctrl) and NELF knockdown cells during granulocytic differentiation (original magnification  $\times 200$ ). The percentages of different cell types at various time points during differentiation are shown on the bar charts. Quantitative results represent average percentages by counting 100 cells per experiment from 3 independent experiments. NES, normalized enrichment score.

NELF-depleted cells are significantly enriched for genes inhibited by differentiation (Figure 5C). Together, these data strongly suggest premature activation of the granulocytic transcription program in progenitor cells when NELF is depleted.

Consistent with the change of transcription profile, MGG staining revealed that NELF-depleted progenitor cells morphologically resemble early-stage granulocytes (Figure 5D). Moreover, when induced to differentiation, NELF-depleted cells showed more accelerated maturation than control cells (Figure 5D). In summary, these data indicate that removing Pol II pausing by depleting NELF promotes granulocytic differentiation.

## Discussion

Transcription pausing has emerged as a crucial control point downstream of transcription initiation in transcription regulation.<sup>26,27</sup> As a major pausing factor, the NELF complex has been shown to play an important role in regulating the pattern of gene expression during development,<sup>24,28</sup> however, little is known of how this complex is manipulated to selectively affect gene transcription in different tissues. By combining high-resolution genomic analysis of transcriptionally competent Pol II with a functional dissection of NELF activity in mammalian hematopoietic progenitors, our current work has identified a dynamic change of transcription pausing via regulating

NELF protein stability as a novel mechanism regulating hematopoietic differentiation. In both murine myeloblastic cell line and human primary HSPCs, induction of granulocytic differentiation triggers a rapid turnover of NELF protein mediated by the proteasome, leading to a genome-wide reduction of transcription pausing. Functional studies revealed that sustained expression of NELF inhibits granulocytic differentiation, whereas depleting NELF in HSPCs causes loss of Pol II pausing accompanied by activation of granulocytic transcription program and diminished expression of progenitor markers, resulting in accelerated granulocytic differentiation. Thus, our studies not only reveal a cellular intrinsic requirement for altering NELF-mediated Pol II pausing during granulocytic differentiation, but also unveiled a cell-context-specific mechanism regulating pausing via modulating NELF protein stability.

NELF subunits are interdependent for their protein stability.<sup>21</sup> Our western blot analysis revealed that NELF-E is the most prominently downregulated subunit in both human and mouse cells, suggesting it as the primary member among the 4 subunits targeted for active protein turnover upon granulocytic differentiation. Supporting this view, overexpression of NELF-E alone was sufficient to block granulocytic differentiation and partially restore the expression of other subunits. Regulation of protein stability has been found as a mechanism affecting other regulators of Pol II elongation, including the components in the super elongation complexes such as AFF1, AFF4, and ELL2, which are regulated by Siah1-mediated polyubiquitination.<sup>29</sup> The fact that NELF downregulation is found in granulocytes but not erythrocytes suggests the existence of lineage-specific regulators. There are multiple ubiquitin E3 ligases highly expressed in granulocytes. Testing these factors in future will help identify the regulators of NELF protein.

NELF and transcription pausing have been proposed to play both positive and negative roles in transcription. On some genes, loss of pausing leads to gene activation by increasing release of Pol II into their gene body.<sup>9</sup> On the other hand, previous studies also found that paused Pol II is required for gene expression by antagonizing nucleosome assembly around the promoter to maintain a permissive chromatin state.<sup>11,12</sup> The identification of both upregulated and downregulated genes in our study is consistent with the dual role of pausing in transcription regulation. Moreover, our results extend previous studies by suggesting that whether pausing inhibits or promotes gene expression may depend on the level of pausing on the target genes. Genes with a high pausing level may rely more on paused Pol II to maintain transcription than genes with a low level of pausing, possibly because high-level paused Pol II competes better with nucleosomes to maintain promoter accessibility.

An important role of preloaded, paused Pol II is to keep genes in a poised state for rapid and synchronized activation upon receipt of developmental cues.<sup>30-33</sup> A major mechanism to achieve rapid release of paused Pol II is through the recruitment of P-TEFb,<sup>27,34-36</sup> which leads to NELF phosphorylation and subsequent dissociation

from chromatin. Our finding provides an alternative mechanism for rapid pause release, which is through modulating NELF abundance. To our knowledge, this is the first study showing such a regulation mechanism of NELF. Although this novel regulation of pausing was found in granulocytes but not in erythroid cells, it is known that erythroid differentiation also requires rapid pause release, which is mediated by P-TEFb recruitment as reported in our previous studies.<sup>37</sup> Thus, both mechanisms (P-TEFb recruitment and NELF modulation) are used in hematopoiesis to regulate lineage differentiation. It will be interesting to investigate how distinct mechanisms are selected to regulate different blood lineages. Notably, regulation of Pol II pausing by modulating the abundance of pausing or elongation factors is certainly not limited to hematopoietic tissues. A recent study revealed differential expression of some super elongation complex components between neural stem cells and their differentiated progeny.<sup>38</sup> Moreover, a variety of human cancer cells have altered expression of NELF subunits.<sup>39-41</sup> Our work is in line with these studies, suggesting that regulating the abundance of pausing/elongation factors may play an important role in normal and malignant cellular development. Understanding the mechanisms involved in these regulation processes is therefore of the utmost importance for understanding and treating human disease associated with dysregulated transcription elongation.

## Acknowledgments

The authors thank Anusha Nagari and Tulip Nandu for advice on bioinformatics, and Shino Murakami and Hector Franco for technical consulting on GRO-seq experiments.

This work was supported by the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases grants R00DK088963 and R01DK105287 [X.B.]; National Heart, Lung, and Blood Institute grant R01HL089966 [L.J.-S.H.]), the Cancer Prevention Research Institute of Texas (CPRIT R1115 [X.B.]), and the Cecil H. and Ida Green Center Training Program in Reproductive Biology Sciences Research at University of Texas Southwestern Medical Center.

## Authorship

Contribution: X.L. performed experiments, analyzed results, and contributed to writing; A.A.G. and V.S.M. analyzed GRO-seq data; M.T., K.N., H.Y. and L.J.-S.H. contributed to some experiments; and X.B. designed and supervised all experiments and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Xiaoying Bai, Department of Obstetrics and Gynecology, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, J7.130B, Dallas, TX 75390; e-mail: xiaoying.bai@utsouthwestern.edu.

## References

1. Gilmour DS. Promoter proximal pausing on genes in metazoans. *Chromosoma*. 2009;118(1):1-10.
2. Adelman K, Lis JT. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. *Nat Rev Genet*. 2012;13(10):720-731.
3. Chiba K, Yamamoto J, Yamaguchi Y, Handa H. Promoter-proximal pausing and its release: molecular mechanisms and physiological functions. *Exp Cell Res*. 2010;316(17):2723-2730.



4. Cheng B, Price DH. Properties of RNA polymerase II elongation complexes before and after the P-TEFb-mediated transition into productive elongation. *J Biol Chem*. 2007;282(30):21901-21912.
5. Yamaguchi Y, Shibata H, Handa H. Transcription elongation factors DSIF and NELF: promoter-proximal pausing and beyond. *Biochim Biophys Acta*. 2013;1829(1):98-104.
6. Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. *Mol Cell*. 2006;23(3):297-305.
7. Zhou Q, Li T, Price DH. RNA polymerase II elongation control. *Annu Rev Biochem*. 2012;81:119-143.
8. Wada T, Takagi T, Yamaguchi Y, Watanabe D, Handa H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro. *EMBO J*. 1998;17(24):7395-7403.
9. Aida M, Chen Y, Nakajima K, Yamaguchi Y, Wada T, Handa H. Transcriptional pausing caused by NELF plays a dual role in regulating immediate-early expression of the junB gene. *Mol Cell Biol*. 2006;26(16):6094-6104.
10. Yamaguchi Y, Takagi T, Wada T, et al. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. *Cell*. 1999;97(1):41-51.
11. Gilchrist DA, Nechaev S, Lee C, et al. NELF-mediated stalling of Pol II can enhance gene expression by blocking promoter-proximal nucleosome assembly. *Genes Dev*. 2008;22(14):1921-1933.
12. Gilchrist DA, Dos Santos G, Fargo DC, et al. Pausing of RNA polymerase II disrupts DNA-specified nucleosome organization to enable precise gene regulation. *Cell*. 2010;143(4):540-551.
13. Gilchrist DA, Fromm G, dos Santos G, et al. Regulating the regulators: the pervasive effects of Pol II pausing on stimulus-responsive gene networks. *Genes Dev*. 2012;26(9):933-944.
14. Pan H, Qin K, Guo Z, et al. Negative elongation factor controls energy homeostasis in cardiomyocytes. *Cell Reports*. 2014;7(1):79-85.
15. Woo AJ, Moran TB, Schindler YL, et al. Identification of ZBP-89 as a novel GATA-1-associated transcription factor involved in megakaryocytic and erythroid development. *Mol Cell Biol*. 2008;28(8):2675-2689.
16. Amrein PC, Stossel TP. Prevention of degradation of human polymorphonuclear leukocyte proteins by diisopropylfluorophosphate. *Blood*. 1980;56(3):442-447.
17. Franco HL, Nagari A, Kraus WL. TNF $\alpha$  signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome. *Mol Cell*. 2015;58(1):21-34.
18. Chae M, Danko CG, Kraus WL. groHMM: a computational tool for identifying unannotated and cell type-specific transcription units from global run-on sequencing data. *BMC Bioinformatics*. 2015;16:222.
19. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. *Science*. 2008;322(5909):1839-1842.
20. Gupta D, Shah HP, Malu K, Berliner N, Gaines P. Differentiation and characterization of myeloid cells. *Curr Protoc Immunol*. 2014;104:Unit 22F.25.
21. Narita T, Yamaguchi Y, Yano K, et al. Human transcription elongation factor NELF: identification of novel subunits and reconstitution of the functionally active complex. *Mol Cell Biol*. 2003;23(6):1863-1873.
22. Core LJ, Waterfall JJ, Lis JT. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. *Science*. 2008;322(5909):1845-1848.
23. Muse GW, Gilchrist DA, Nechaev S, et al. RNA polymerase is poised for activation across the genome. *Nat Genet*. 2007;39(12):1507-1511.
24. Zeitlinger J, Stark A, Kellis M, et al. RNA polymerase stalling at developmental control genes in the *Drosophila melanogaster* embryo. *Nat Genet*. 2007;39(12):1512-1516.
25. Min IM, Waterfall JJ, Core LJ, Munroe RJ, Schimenti J, Lis JT. Regulating RNA polymerase pausing and transcription elongation in embryonic stem cells. *Genes Dev*. 2011;25(7):742-754.
26. Levine M. Paused RNA polymerase II as a developmental checkpoint. *Cell*. 2011;145(4):502-511.
27. Liu X, Kraus WL, Bai X. Ready, pause, go: regulation of RNA polymerase II pausing and release by cellular signaling pathways. *Trends Biochem Sci*. 2015;40(9):516-525.
28. Chen K, Johnston J, Shao W, Meier S, Staber C, Zeitlinger J. A global change in RNA polymerase II pausing during the *Drosophila* midblastula transition. *eLife*. 2013;2:e00861.
29. Liu M, Hsu J, Chan C, Li Z, Zhou Q. The ubiquitin ligase Siah1 controls ELL2 stability and formation of super elongation complexes to modulate gene transcription. *Mol Cell*. 2012;46(3):325-334.
30. Gaertner B, Johnston J, Chen K, et al. Poised RNA polymerase II changes over developmental time and prepares genes for future expression. *Cell Reports*. 2012;2(6):1670-1683.
31. Lagha M, Bothma JP, Esposito E, et al. Paused Pol II coordinates tissue morphogenesis in the *Drosophila* embryo. *Cell*. 2013;153(5):976-987.
32. Danko CG, Hah N, Luo X, et al. Signaling pathways differentially affect RNA polymerase II initiation, pausing, and elongation rate in cells [published correction appears in *Mol Cell*. 2013;50(5):778]. *Mol Cell*. 2013;50(2):212-222.
33. Williams LH, Fromm G, Gokey NG, et al. Pausing of RNA polymerase II regulates mammalian developmental potential through control of signaling networks. *Mol Cell*. 2015;58(2):311-322.
34. Lis JT, Mason P, Peng J, Price DH, Werner J. P-TEFb kinase recruitment and function at heat shock loci. *Genes Dev*. 2000;14(7):792-803.

35. Kininis M, Isaacs GD, Core LJ, Hah N, Kraus WL. Postrecruitment regulation of RNA polymerase II directs rapid signaling responses at the promoters of estrogen target genes. *Mol Cell Biol.* 2009;29(5):1123-1133.
36. Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. *Nat Rev Cancer.* 2010;10(10):721-728.
37. Bai X, Kim J, Yang Z, et al. TIF1gamma controls erythroid cell fate by regulating transcription elongation. *Cell.* 2010;142(1):133-143.
38. Liu K, Shen D, Shen J, et al. The super elongation complex drives neural stem cell fate commitment. *Dev Cell.* 2017;40(6):537-551.
39. Sun J, Watkins G, Blair AL, et al. Deregulation of cofactor of BRCA1 expression in breast cancer cells. *J Cell Biochem.* 2008;103(6):1798-1807.
40. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012;2(5):401-404.
41. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal.* 2013;6(269):pl1.